Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
Diclofenac Sodium and Misoprostol Delayed Release Tablets USP, 50mg/200 mcg and 75mg/200 mcg had annual sales of USD 13 mn in the United States
The proposed initiative is conceptualised with an objective to identify, support, and promote innovative research ideas in healthcare research
Diclofenac Sodium Topical Solution USP, 2% w/w has an estimated market size of US $512 million for twelve months ending Sep 2022 according to IQVIA
GlobalData’s ‘Pharmaceutical Intelligence Center’ observes that India is still in the nascent stage of developing these potential therapies as currently only four cell/gene therapy molecules are being developed in the country.
Company raises the annual revenue guidance from mid-teens to high teens
Syngene's collaboration with Zoetis started in 2011
This is the 142nd ANDA (including 8 tentative approvals received) out of Eugia Pharma Specialty Group (EPSG) facilities, manufacturing both oral and sterile specialty products.
The patient, who was previously diagnosed with osteoarthritis, was prescribed hip replacement surgery as the best and most effective solution for his condition
Turn has developed a novel cell rejuvenating platform with significant potential for application in an array of age-related diseases
Subscribe To Our Newsletter & Stay Updated
